Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Margaret D. Rosa is active.

Publication


Featured researches published by Margaret D. Rosa.


Cell Adhesion and Communication | 1995

Vascular Cell Adhesion Molecule (VCAM)-Ig Fusion Protein Defines Distinct Affinity States of the Very Late Antigen-4 (VLA-4) Receptor

Aniela Jakubowski; Margaret D. Rosa; Sarah A. Bixler; Roy R. Lobb; Linda C. Burkly

The Very Late Antigen-4 receptor (VLA-4) (alpha 4 beta 1) is constitutively expressed on leukocytes and plays a role in cell trafficking, activation and development through its interaction with two alternative ligands, Vascular Cell Adhesion Molecule (VCAM-1) and fibronectin (FN). VLA-4-dependent cell adhesion is augmented by various stimuli, such as divalent cations, certain beta 1-specific monoclonal antibodies (mAbs) and cell activation. However, the steps of the adhesive process which they affect are currently undefined. In order to investigate whether or not these stimuli affect the primary step, VLA-4/ligand binding, we employed a recombinant VCAM-IgG fusion protein (VCAM-Ig) as a soluble ligand for VLA-4. Using this soluble ligand, we have directly demonstrated that the VLA-4 receptor can exist in at least three different affinity states on the cell surface. Two distinct high affinity states are induced on normal peripheral blood T cells, one by the anti-beta 1 mAb TS2/16, and one of 15-20 fold higher affinity by the divalent cation Mn2+. Interestingly, activation through the T cell receptor (TcR), through CD31 or by the Macrophage Inflammatory Protein-1 beta chemokine (MIP-1 beta) do not detectably increase VLA-4 affinity although they do augment VLA-4 dependent cell adhesion in vitro. Thus, VCAM-Ig binding defines high affinity VLA-4 receptors, revealing unique effects of the TS2/16 mAb and Mn2+ cations in vitro, and distinguishes VLA-4/VCAM interactions from subsequent steps in cell adhesion.


Biochemical and Biophysical Research Communications | 1991

Expression and functional characterization of a soluble form of vascular cell adhesion molecule 1

Roy R. Lobb; Gloria Chi-Rosso; Diane R. Leone; Margaret D. Rosa; Barbara Newman; Stefan Luhowskyj; Lauralee Osborn; Susan Schiffer; Christopher D. Benjamin; Irene Dougas; Catherine Hession; Pingchang Chow

Vascular cell adhesion molecule 1 (VCAM1) is a leukocyte adhesion molecule induced on human endothelium in vitro and in vivo by inflammatory stimuli. A truncated cDNA for VCAM1 was constructed, stably expressed in Chinese Hamster Ovary (CHO) cells, and the secreted recombinant soluble form of VCAM1 (rsVCAM1) purified to homogeneity by immunoaffinity chromatography. Immobilized rsVCAM1 is a functional adhesion protein, and selectively binds only VLA4-expressing cells, including human B and T lymphocytes, NK cells, and certain lymphoblastoid cell lines. T cell subset analyses indicate preferential binding of CD8+ memory cells. rsVCAM1 should prove valuable for the further study of the role of VCAM1 during inflammatory and immune responses in vivo.


Biochemical and Biophysical Research Communications | 1990

A blocking monoclonal antibody to endothelial-leukocyte adhesion molecule-1 (ELAM1)

Christopher D. Benjamin; Irene Dougas; Gloria Chi-Rosso; Stefan Luhowskyj; Margaret D. Rosa; Barbara Newman; Laurelee Osborn; Catherine Hession; Susan Goelz; Kathy McCarthy; Roy R. Lobb

ELAM1 is a leukocyte adhesion molecule induced on human umbilical vein endothelial cells (HUVECs) by inflammatory cytokines. Balb/C mice were immunized with COS cells transiently expressing cell-surface ELAM1 after transfection with ELAM1 cDNA. After fusion, ELAM1-specific monoclonal antibodies (Mabs) were identified by selective adhesion to ELAM1-expressing, but not control, CHO cells, and to cytokine-treated but not untreated HUVECs. One Mab, designated BB11, binds to and immunoprecipitates ELAM1 expressed on HUVECs, COS and CHO cells. BB11 blocks the interaction of ELAM1 with human PMN, the human myelomonocytic cell line HL60, and the human colon carcinoma line HT29.


Journal of Experimental Medicine | 1993

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.

Glenn T. Miller; Paula S. Hochman; Werner Meier; Richard Tizard; Sarah A. Bixler; Margaret D. Rosa; Barbara P. Wallner


Archive | 1990

ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)

Catherine Hession; Roy R. Lobb; Susan Goelz; Laurelee Osborn; Christopher D. Benjamin; Margaret D. Rosa


European Journal of Immunology | 1991

Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation

Linda C. Burkly; Aniela Jakubowski; Barbara Newman; Margaret D. Rosa; Gloria Chi-Rosso; Roy R. Lobb


AIDS Research and Human Retroviruses | 1997

A Humanized Form of a CD4-Specific Monoclonal Antibody Exhibits Decreased Antigenicity and Prolonged Plasma Half-Life in Rhesus Monkeys While Retaining Its Unique Biological and Antiviral Properties

Keith A. Reimann; Wenyu Lin; Sarah A. Bixler; Beth Browning; Barbara Ehrenfels; Jodie Lucci; Konrad Miatkowski; Dian Olson; Thomas H. Parish; Margaret D. Rosa; Frederick B. Oleson; Yen Ming Hsu; Eduardo A. Padlan; Norman L. Letvin; Linda C. Burkly


Archive | 1985

Modified tissue plasminogen activators

Joseph J. Rosa; Margaret D. Rosa


Archive | 1989

DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Catherine Hession; Roy R. Lobb; Susan Goelz; Laurelee Osborn; Christopher D. Benjamin; Margaret D. Rosa


Archive | 1992

CD2-binding domain of lymphocyte function associated antigen 3

Barbara P. Wallner; Glenn T. Miller; Margaret D. Rosa

Collaboration


Dive into the Margaret D. Rosa's collaboration.

Researchain Logo
Decentralizing Knowledge